The National Eye Institute Visual Function Question naire-25 , Impact of Vision Impairment and Treatment Satisfaction Survey-Intraocular Pressure had the highest number of positive ratings in the content validity assessment .
Conclusion This study provides a descriptive catalogue of vision-specific PRO instruments , to inform the choice of an appropriate measure of patient-reported outcomes in a glaucoma context
Purpose To identify  vision Patient-Reported Outcomes instruments relevant to glaucoma and assess their content validity .
Treatment and vision-related quality of life in the early manifest glaucoma trial.
PURPOSE To evaluate the effect of treatment , visual function , and other factors on vision-targeted health-related quality of life ( HRQOL ) of patients with early glaucoma . DESIGN R and omized clinical trial . PARTICIPANTS Two hundred fifty-five patients with newly detected open-angle glaucoma and repeatable early visual field ( VF ) defects , 50 to 80 years old ( 66 % female ) . METHODS Patients were r and omized to receive either betaxolol plus laser trabeculoplasty in eligible eye(s ) or no initial treatment and had ophthalmologic examinations every 3 months . A Swedish translation of the 25-item National Eye Institute Visual Function Question naire ( NEI VFQ-25 ) was self-administered at 2 follow-up visits ( 3 and 6 years after r and omization ) . MAIN OUTCOME Multiple linear regression analyses determined the effect of treatment and other factors on ( 1 ) VFQ-25 composite scores at the first administration and ( 2 ) change in scores between administrations . RESULTS Two hundred thirty-three patients had 1 NEI VFQ-25  administration and 167 patients had 2 administrations . Internal consistency reliability was high for the composite VFQ-25 score ( Cronbach alpha = 0.88 ) and satisfactory ( alpha > or = 0.76 ) for most subscale scores . At the first administration , the composite score was high ( 88.8+/-11.7 ) . Mean subscale scores were also generally high ( 98.0 - 58.3 ) and were similar for each study group when analyzed separately . Most lower subscale scores were modestly but significantly related to worse visual acuity ( VA ) or mean deviation ( MD ) ( better eye , r = 0.15 - 0.35 ) . Composite scores were similar for treated and untreated patients . Lower composite scores were associated with low VA in the better eye ( worse than 0.70 ) and worse perimetric MD ( < 4.16 decibels ) and nuclear lens opacities ( Lens Opacities Classification System II grade > or = 2 ) , but not with age , gender , VF progression , intraocular pressure , cardiovascular disease , or hypertension . Between VFQ-25 administrations , larger decreases in the composite score were associated with larger decreases in VA ( P<0.05 ) , female gender ( P = 0.001 ) , and older age at first administration ( P = 0.006 ) . Treatment ( assigned at r and omization or later in the study ) was not associated with change in HRQOL . CONCLUSIONS Results suggest that absence or delay of treatment did not influence vision-targeted HRQOL in these newly diagnosed glaucoma patients . However , visual function affected vision-targeted quality of life up to 6 years after Early Manifest Glaucoma Trial enrollment
The National Eye Institute Visual Function Question naire-25 , Impact of Vision Impairment and Treatment Satisfaction Survey-Intraocular Pressure had the highest number of positive ratings in the content validity assessment .
Conclusion This study provides a descriptive catalogue of vision-specific PRO instruments , to inform the choice of an appropriate measure of patient-reported outcomes in a glaucoma context
Purpose To identify  vision Patient-Reported Outcomes instruments relevant to glaucoma and assess their content validity .